Průběžná zpráva o klinickém hodnocení léčiva

Title in English Interim Report on Clinical Drug Evaluation


Year of publication 2022
MU Faculty or unit

Faculty of Medicine

Description Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR). Clinical trial RASmiR (EudraCT number 2018-001210-15) - Annual report describes the progress and current status of the clinical trial in the period 01.08.2021 – 31.07.2022. It summarizes changes in the CT centers and the status of patient recruitment to date. It also provides an overview of clinical trial subjects, safety information and information about the study treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info